This means that it could be used in combination with GLP-1s to possibly enhance weight loss or simply offer an alternative to these drugs. Second, and one reason why someone might choose a CB1 drug ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The ...

Skye Bioscience (SKYE) announced preliminary data from a diet-induced obesity model in mice. Skye’s CB1-inhibiting antibody, nimacimab, ...

The data are being presented as a Poster Presentation titled: “Induction and Maintenance Regimens with CB1 Inverse Agonist ... that CRB-913 provides additive weight loss when combined with ...

Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...